Compass Therapeutics is a clinical-stage biopharmaceutical company focused on proprietary antibody drugs for cancer. Its science centers on the interplay of angiogenesis, the immune system and tumor growth, with candidates designed to block tumor blood-vessel support, activate anti-tumor immunity and ease tumor-driven immunosuppression. A lead program is tovecimig, a DLL4 × VEGF-A bispecific antibody studied in advanced biliary tract and other solid tumors, alone and in combination.
| Quarter | Revenue | YoY % | Earnings | YoY % |
|---|---|---|---|---|
| Q2 2025 | 0 | — | -19.9 | — |
| Q3 2025 | 0 | — | -14.3 | — |
| Q4 2025 | 0 | — | -15.7 | — |
| Q1 2026 | 0 | — | -18.3 | — |
| Q2 2026 | 0 | — | -25.1 | — |
All markets — KeepWinning global stock screener
Other companies on Nasdaq: Atea Pharmaceuticals, Inc. (AVIR), The Metals Royalty Company Inc. (TMCR), Weyco Group, Inc. (WEYS), Eupraxia Pharmaceuticals Inc. (EPRX), Plumas Bancorp (PLBC), FRP Holdings, Inc. (FRPH)